Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Bioorg Chem ; 150: 107584, 2024 Sep.
Article in English | MEDLINE | ID: mdl-38964146

ABSTRACT

Developing multitargeted ligands as promising therapeutics for Alzheimer's disease (AD) has been considered important. Herein, a novel class of cinnamamide/ester-triazole hybrids with multifaceted effects on AD was developed based on the multitarget-directed ligands strategy. Thirty-seven cinnamamide/ester-triazole hybrids were synthesized, with most exhibiting significant inhibitory activity against Aß-induced toxicity at a single concentration in vitro. The most optimal hybrid compound 4j inhibited copper-induced Aß toxicity in AD cells. its action was superior to that of donepezil and memantine. It also moderately inhibited intracellular AChE activity and presented favorable bioavailability and blood-brain barrier penetration with low toxicity in vivo. Of note, it ameliorated cognitive impairment, neuronal degeneration, and Aß deposition in Aß1-42-injured mice. Mechanistically, the compound regulated APP processing by promoting the ADAM10-associated nonamyloidogenic signaling and inhibiting the BACE1-mediated amyloidogenic pathway. Moreover, it suppressed intracellular AChE activity and tau phosphorylation. Therefore, compound 4j may be a promising multitargeted active molecule against AD.


Subject(s)
Alzheimer Disease , Amyloid beta-Peptides , Cinnamates , Triazoles , Alzheimer Disease/drug therapy , Alzheimer Disease/metabolism , Animals , Triazoles/chemistry , Triazoles/pharmacology , Triazoles/chemical synthesis , Cinnamates/chemistry , Cinnamates/pharmacology , Cinnamates/chemical synthesis , Humans , Mice , Amyloid beta-Peptides/metabolism , Amyloid beta-Peptides/antagonists & inhibitors , Structure-Activity Relationship , Molecular Structure , Esters/chemistry , Esters/pharmacology , Esters/chemical synthesis , Dose-Response Relationship, Drug , Acetylcholinesterase/metabolism , Cholinesterase Inhibitors/chemistry , Cholinesterase Inhibitors/pharmacology , Cholinesterase Inhibitors/chemical synthesis , Drug Discovery , Neuroprotective Agents/chemistry , Neuroprotective Agents/pharmacology , Neuroprotective Agents/chemical synthesis , Peptide Fragments/metabolism , Peptide Fragments/antagonists & inhibitors , Male
SELECTION OF CITATIONS
SEARCH DETAIL